These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 445502)

  • 41. Analgesia for Gynecologic Oncologic Surgeries: A Narrative Review.
    Patel K; Shergill S; Vadivelu N; Rajput K
    Curr Pain Headache Rep; 2022 Jan; 26(1):1-13. PubMed ID: 35118596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peritoneal Metastasis: Current Status and Treatment Options.
    Roth L; Russo L; Ulugoel S; Freire Dos Santos R; Breuer E; Gupta A; Lehmann K
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008221
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial.
    Raoof M; Malhotra G; Kohut A; O'Leary M; Frankel P; Tran T; Fakih M; Chao J; Lim D; Woo Y; Paz IB; Lew M; Cristea MC; Rodriguez-Rodriguez L; Fong Y; Blakely A; Whelan R; Reymond MA; Merchea A; Dellinger TH
    Ann Surg Oncol; 2022 Jan; 29(1):175-185. PubMed ID: 34387765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Status of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
    Yang SY; Kang JH; Kim HS; Han YD; Min BS; Lee KY
    J Gastrointest Oncol; 2019 Dec; 10(6):1251-1265. PubMed ID: 31949946
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fluorescent Nanoparticles for the Guided Surgery of Ovarian Peritoneal Carcinomatosis.
    Mangeolle T; Yakavets I; Marchal S; Debayle M; Pons T; Bezdetnaya L; Marchal F
    Nanomaterials (Basel); 2018 Jul; 8(8):. PubMed ID: 30050022
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective.
    Neuwirth MG; Alexander HR; Karakousis GC
    J Gastrointest Oncol; 2016 Feb; 7(1):18-28. PubMed ID: 26941981
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A meta-analysis: neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma FIGO stageIII and IV.
    Dai-yuan M; Bang-xian T; Xian-fu L; Ye-qin Z; Hong-Wei C
    World J Surg Oncol; 2013 Oct; 11():267. PubMed ID: 24112995
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion.
    Haslinger M; Francescutti V; Attwood K; McCart JA; Fakih M; Kane JM; Skitzki JJ
    Cancer Med; 2013 Jun; 2(3):334-42. PubMed ID: 23930210
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Surgical debulking of ovarian cancer: what difference does it make?
    Schorge JO; McCann C; Del Carmen MG
    Rev Obstet Gynecol; 2010; 3(3):111-7. PubMed ID: 21364862
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Contemporary considerations for neoadjuvant chemotherapy in primary ovarian cancer.
    Schwartz PE
    Curr Oncol Rep; 2009 Nov; 11(6):457-65. PubMed ID: 19840523
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression.
    Napoletano C; Bellati F; Landi R; Pauselli S; Marchetti C; Visconti V; Sale P; Liberati M; Rughetti A; Frati L; Panici PB; Nuti M
    J Cell Mol Med; 2010 Dec; 14(12):2748-59. PubMed ID: 19780872
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.
    Koppe MJ; Boerman OC; Oyen WJ; Bleichrodt RP
    Ann Surg; 2006 Feb; 243(2):212-22. PubMed ID: 16432354
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of interval debulking surgery in ovarian cancer.
    van der Burg ME; Vergote I;
    Curr Oncol Rep; 2003 Nov; 5(6):473-81. PubMed ID: 14521806
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
    Kuhn W; Schmalfeldt B; Reuning U; Pache L; Berger U; Ulm K; Harbeck N; Späthe K; Dettmar P; Höfler H; Jänicke F; Schmitt M; Graeff H
    Br J Cancer; 1999 Apr; 79(11-12):1746-51. PubMed ID: 10206287
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials.
    Warwick J; Kehoe S; Earl H; Luesley D; Redman C; Chan KK
    Br J Cancer; 1995 Dec; 72(6):1513-7. PubMed ID: 8519669
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of ovarian cancer: the state of the art.
    Einhorn N
    Med Oncol Tumor Pharmacother; 1993; 10(3):139-42. PubMed ID: 8264259
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Second look laparotomy in the management of epithelial cell carcinoma of the ovary.
    Mead GM; Williams CJ; MacBeth FR; Boyd IE; Whitehouse JM
    Br J Cancer; 1984 Aug; 50(2):185-91. PubMed ID: 6466536
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chemotherapy in advanced ovarian cancer.
    Rodenburg CJ; Cleton FJ
    J Cancer Res Clin Oncol; 1984; 107(2):99-105. PubMed ID: 6371017
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radiation therapy in the treatment of patients with cancer of the ovary.
    Bush RS
    Bull N Y Acad Med; 1983 Oct; 59(8):691-710. PubMed ID: 6357333
    [No Abstract]   [Full Text] [Related]  

  • 60. The influence of cytoreductive surgery on the response to chemotherapy of a rat renal cancer.
    deVere White R; Deitch AD; Hong WK; Olsson CA
    Urol Res; 1985; 13(1):35-8. PubMed ID: 3992765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.